NIH Funding Opportunities
Each year, the National Institutes of Health (NIH) invests more than $30 billion in medical research funding to a variety of research-related programs.
The following grant opportunities have upcoming deadlines.
Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R33)
Letter of Intent Due: 30 days prior to application due date
Deadline: June 29, 2015
The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory (R33) clinical trial grant applications that focus on the early phases of natural product development, during which basic and mechanistic research is translated into clinically testable hypotheses and tested in healthy volunteers or a clinical population. In this approach, clinical trials should be designed to increase knowledge of the use of the intervention, the underlying condition, and the mechanism of action through which the natural product produces clinical benefit. Applications for this FOA must have preliminary data demonstrating that the natural product has an impact on a biological signature in humans and that the natural product is bioavailable to exert this effect in humans. This FOA provides support for studies to confirm the natural product’s effect on the biological signature in a larger sample and assess the relationship between the biological signature and changes in functional outcomes or clinical symptoms.
Phased Innovation Award for Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R21/R33)
Letter of Intent Due: 30 days prior to application due date
Deadline: June 22, 2015
The purpose of this Funding Opportunity Announcement (FOA) is to encourage Phased Innovation (R21/R33) grant applications that focus on the early phases of natural product development, during which basic and mechanistic research is translated into clinically testable hypotheses and tested in healthy volunteers or a clinical population. In this approach, clinical studies and trials should be designed to increase knowledge of the use of the intervention, the underlying condition and the mechanism of action through which the natural product produces clinical benefit.
